David Windley
Jefferies LLC, Research Division

All right, folks. Thanks for joining us. Dave Windley with Jefferies Healthcare Equity Research. We're here at Jefferies 2026 Global Healthcare Conference. And on the Wednesday afternoon, glad to be joined by Certara and the team's Johns. Jon Resnick newly joined -- recently joined CEO; and John Gallagher, the company's CFO. So, thanks very much for being here. Glad to see you and great to have you.

Jon Resnick, I wanted to start us off with a question on the realignment of the company, which I thought was interesting and maybe intuitive for a guy like me after the fact, but I might not have thought of it myself. So, talk about your MID3 and your ACE, I think you're calling it, realignment of the segments and what implications that has.

Jon Resnick
CEO & Director

Okay. Well, thank you, Dave, for having us here today. It's great to be with you. So organizationally, we did announce some changes. It's been a pretty active first few months within Certara. I started January 1. We've been very focused strategically on how we set ourselves up for broader growth opportunities. So, I spent a lot of time talking to customers around what's on top of their minds to regulators in terms of trends and growth trajectory and then did a fair amount of work with our internal teams trying to understand where some of the distinctive opportunities exist. So, in essence, our mission within the company is to disrupt clinical trials or transform clinical trials, clinical development for good.